Revital Amiaz1, Ilan Kent2, Katya Rubinstein2, Ben Ami Sela2, Daniel Javitt3, Mark Weiser1. 1. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 2. Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 3. Nathan Klein Institute, Orangeburg, New York, U.S.A.
Abstract
BACKGROUND: Hypofunction of NMDA receptor-mediated neurotransmission might play a critical role in schizophrenia. Sarcosine, N- methylglycine and inhibitor of the glycine transporter-1 (Gly-T1), has been suggested as a novel treatment for schizophrenia. METHODS: Open label sarcosine was added to 22 stabilized patients: 5 patients received 2 gm/d, and 17 received 4gm/d. Pharmacokinetics samples, clinical and cognitive parameters using PANSS, CGI and MCCB were collected for all patients. RESULTS: Significant improvement was observed after one week of treatment on PANSS sub-scale of 'positive symptoms' (Z= -2.68; P=0.007) and 'general psychopathology' (Z= -3.02; P=0.003), an improvement in PANSS total score and CGI-S showed a trend (Z= -2.72; P=0.06; Z=-2.69; P=0.08). Speed of processing (MCCB subscale) improved significantly (Z=-2.13; P=0.03). Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively. LIMITATIONS: This was a short period, open label pilot study with small sample size per dosage group. CONCLUSIONS: Sarcosine is a safe compound and might be efficacious in the treatment of schizophrenia.
BACKGROUND: Hypofunction of NMDA receptor-mediated neurotransmission might play a critical role in schizophrenia. Sarcosine, N- methylglycine and inhibitor of the glycine transporter-1 (Gly-T1), has been suggested as a novel treatment for schizophrenia. METHODS: Open label sarcosine was added to 22 stabilized patients: 5 patients received 2 gm/d, and 17 received 4gm/d. Pharmacokinetics samples, clinical and cognitive parameters using PANSS, CGI and MCCB were collected for all patients. RESULTS: Significant improvement was observed after one week of treatment on PANSS sub-scale of 'positive symptoms' (Z= -2.68; P=0.007) and 'general psychopathology' (Z= -3.02; P=0.003), an improvement in PANSS total score and CGI-S showed a trend (Z= -2.72; P=0.06; Z=-2.69; P=0.08). Speed of processing (MCCB subscale) improved significantly (Z=-2.13; P=0.03). Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively. LIMITATIONS: This was a short period, open label pilot study with small sample size per dosage group. CONCLUSIONS:Sarcosine is a safe compound and might be efficacious in the treatment of schizophrenia.
Authors: Henry Sershen; Audrey Hashim; David S Dunlop; Raymond F Suckow; Tom B Cooper; Daniel C Javitt Journal: Neurochem Res Date: 2016-02-08 Impact factor: 3.996
Authors: Natalie de la Garrigue; Juliana Glasser; Pejman Sehatpour; Dan V Iosifescu; Elisa Dias; Marlene Carlson; Constance Shope; Tarek Sobeih; Tse-Hwei Choo; Melanie M Wall; Lawrence S Kegeles; James Gangwisch; Megan Mayer; Stephanie Brazis; Heloise M De Baun; Stephanie Wolfer; Dalton Bermudez; Molly Arnold; Danielle Rette; Amir M Meftah; Melissa Conant; Jeffrey A Lieberman; Joshua T Kantrowitz Journal: J Psychiatr Brain Sci Date: 2020-08-06
Authors: Julia Cappelli; Pamela Khacho; Boyang Wang; Alexandra Sokolovski; Wafae Bakkar; Sophie Raymond; Nina Ahlskog; Julian Pitney; Junzheng Wu; Prakash Chudalayandi; Adrian Y C Wong; Richard Bergeron Journal: iScience Date: 2021-12-03